Semaglutide oral - Novo Nordisk
At a glance
- Drug Originator Novo Nordisk
- Drug Licenced by Merck Sharp & Dohme
- Drug Class Antidementias; Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Glucagon like peptide 1 receptor agonists
- USA Patent Applicants NOVO
- USA Patents 11
- NDAs 1
- International Patents 148
- Patent Applications 938
Table of Contents

Disclaimer